<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05799898</url>
  </required_header>
  <id_info>
    <org_study_id>CARDIO-03-2022</org_study_id>
    <nct_id>NCT05799898</nct_id>
  </id_info>
  <brief_title>Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors</brief_title>
  <acronym>FAST-TRACK</acronym>
  <official_title>Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors: Prospective Cohort Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Mutualiste Montsouris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Mutualiste Montsouris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective study cohort on patients addressed for suspected cardiovascular event on immune&#xD;
      checkpoint inchibitors.&#xD;
&#xD;
      Longitudinal prospective single center cohort. Inclusion criteria: all patient willing to&#xD;
      particiupate seen in the cardio-oncology unit at our institution for the suspicion of heart&#xD;
      failure, atherosclerosis related event, Tako Tsubo, arrhymias, pericarditis, myocarditis on&#xD;
      antiPD1, antiPDL1, or antiCTLA4 immune checkpoint inhibitors.&#xD;
&#xD;
      Description of patients characteristics, investigations, diagnosis after multidisciplinary&#xD;
      meeting, outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2022</start_date>
  <completion_date type="Anticipated">January 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Major cardiovascular event</measure>
    <time_frame>12 months</time_frame>
    <description>Composite endpoint: acute coronary syndrome, myocarditis, pericarditis, heart failure, Taki Tsubo, ventricvular arrhymias</description>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cancer</condition>
  <condition>Immune Checkpoint Inhibitor</condition>
  <condition>Cardiovascular Complication</condition>
  <condition>Immune-related Adverse Event</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention for research purposes only</intervention_name>
    <description>No intervention for research purposes only</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Endomyocardial biopsies&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults on immune checkpoint inhibitors for cancer treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  all patient referred to the cardio oncology unit for suspected immune related&#xD;
             cardiovascular complication on immune checkpoint inhibitors&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariana Mirabel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Mutualiste Montsouris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabelle Sauret</last_name>
    <phone>+33156616705</phone>
    <email>isabelle.sauret@imm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathalie Bass</last_name>
    <email>nathalie.bass@imm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Intitut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana Mirabel, MD, PhD</last_name>
      <phone>+33156616479</phone>
      <email>mariana.mirabel@imm.fr</email>
    </contact>
    <contact_backup>
      <last_name>Isabelle Sauret, MBs</last_name>
      <phone>+33156616705</phone>
      <email>isabelle.sauret@imm.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 23, 2023</study_first_submitted>
  <study_first_submitted_qc>March 23, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2023</study_first_posted>
  <last_update_submitted>March 23, 2023</last_update_submitted>
  <last_update_submitted_qc>March 23, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

